Top

Published in:

01-03-2018 | Original Article

Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer

Authors: Tetsuhiko Taira, Kiyotaka Yoh, Seisuke Nagase, Kaoru Kubota, Hironobu Ohmatsu, Seiji Niho, Masakatsu Onozawa, Tetsuo Akimoto, Yuichiro Ohe, Koichi Goto

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Abstract

Purpose

The purpose of this phase I/II study was to evaluate the feasibility and efficacy of S-1 plus cisplatin at the recommended schedule with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).

Methods

Eligible patients with LA-NSCLC were treated with cisplatin intravenously at a dose of 60 mg/m² on day 8 plus oral S-1 at a dosage of 40 mg/m² twice per day for two different treatment schedules for up to 4 cycles. Patients also concurrently received 60 Gy of thoracic radiation in 30 fractions. The primary endpoint of the phase II study was the proportion of patients who survived for more than 2 years.

Results

Between August 2005 and October 2010, a total of 45 patients were enrolled in this phase I/II study; their long-term survival was then followed for a median period of 5.8 years. Nineteen of the 39 patients in the phase II study survived for more than 2 years and met the primary endpoint of the study. The median overall survival period was 24.9 months [95% confidence interval (CI) 17.4–74.5 months], and the 2- and 5-year overall survival rates were 51.0 and 43.0%, respectively. The response rate was 85%, and the median progression-free survival period was 13.8 months (95% CI 9.5–27.1 months). Hematological toxicity was mild. Grade 3 febrile neutropenia and pneumonitis was observed in 5 and 5%, respectively.

Conclusion

Our study indicated that S-1 plus cisplatin with concurrent thoracic radiotherapy yielded encouraging survival outcomes and an acceptable safety profile for LA-NSCLC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA 65(1):5–29. https://doi.org/10.3322/caac.21254 PubMed

Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, American Society of Clinical O (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330–353. https://doi.org/10.1200/JCO.2004.09.053 CrossRefPubMed

Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28(23):3739–3745. https://doi.org/10.1200/JCO.2009.24.5050 CrossRefPubMed

Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M (2010) Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28(20):3299–3306. https://doi.org/10.1200/JCO.2009.24.7577 CrossRefPubMed

Horinouchi H, Sekine I, Sumi M, Noda K, Goto K, Mori K, Tamura T (2013) Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. Cancer Sci 104(1):93–97. https://doi.org/10.1111/cas.12028 CrossRefPubMed

Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, Graham DL, Adjei AA, Jett JR, Mayo Clinic NCCTG. (2017) Long-term results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer: NCCTG N0028 (alliance). J Thorac Oncol 12(4):697–703. https://doi.org/10.1016/j.jtho.2016.12.021 CrossRefPubMed

Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17(9):2692–2699. https://doi.org/10.1200/JCO.1999.17.9.2692 CrossRefPubMed

Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543 CrossRefPubMed

Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti Cancer Drugs 7(5):548–557CrossRefPubMed

10.

Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S, Tokyo Cooperative Oncology G (2015) A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 26(7):1401–1408. https://doi.org/10.1093/annonc/mdv190 CrossRefPubMedPubMedCentral

11.

Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, Ichinose Y, Saijo N, Ariyoshi Y, Fukuoka M (2010) A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 5(5):702–706. https://doi.org/10.1097/JTO.0b013e3181ce3e22 CrossRefPubMed

12.

Vokes EE, Weichselbaum RR (1990) Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8(5):911–934. https://doi.org/10.1200/JCO.1990.8.5.911 CrossRefPubMed

13.

Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada M (2000) A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 82(1):104–111. https://doi.org/10.1054/bjoc.1999.0885 CrossRefPubMed

14.

Ichinose Y, Nakai Y, Kudoh S, Semba H, Yoshida S, Nukiwa T, Yamamoto H, Yamane Y, Niitani H (2004) Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10(13):4369–4373. https://doi.org/10.1158/1078-0432.CCR-04-0143 CrossRefPubMed

15.

Yamada Y, Saito H, Oie S, Takechi T, Nakano K, Takeda S (1990) Experimental study of the effect of combined treatment of UFT with CDDP on human solid tumor-xenografts in nude mice. Gan Kagaku Ryoho Cancer Chemother 17(7):1327–1331

16.

Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y (2010) Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 24(5):1307–1313CrossRefPubMed

17.

Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai T, Nishio M (2009) Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101(2):225–231. https://doi.org/10.1038/sj.bjc.6605152 CrossRefPubMedPubMedCentral

18.

Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, Saka H, Nishimura Y, Nakagawa K, Fukuoka M (2011) S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J Thorac Oncol 6(12):2069–2075. https://doi.org/10.1097/JTO.0b013e3182307e5a CrossRefPubMed

19.

Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N (2013) Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer 82(3):449–454. https://doi.org/10.1016/j.lungcan.2013.09.004 CrossRefPubMed

20.

Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K (2015) A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer 87(2):141–147. https://doi.org/10.1016/j.lungcan.2014.11.001 CrossRefPubMed

21.

Seto T, Sasaki T, Yamanaka T (2015) A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L. J Clin Oncol 33:suppl abstr 7512

22.

Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M, Ando M (2013) Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol 8(9):1181–1189. https://doi.org/10.1097/JTO.0b013e3182988348 CrossRefPubMed

23.

Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K (2015) Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol 33(24):2660–2666. https://doi.org/10.1200/JCO.2014.60.0130 CrossRefPubMed

24.

Liu L, Bi N, Ji Z, Li J, Wang J, Wang X, Hui Z, Lv J, Liang J, Zhou Z, Wang Y, Yin W, Wang L (2015) Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy—retrospective analysis of 203 cases. BMC Cancer 15:715. https://doi.org/10.1186/s12885-015-1710-2 CrossRefPubMedPubMedCentral

25.

Kim YH, Mishima M (2016) Consolidation chemotherapy after concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. J Clin Oncol 34(7):767. https://doi.org/10.1200/JCO.2015.63.9393 CrossRefPubMed

Title: Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer
Authors: Tetsuhiko Taira
Kiyotaka Yoh
Seisuke Nagase
Kaoru Kubota
Hironobu Ohmatsu
Seiji Niho
Masakatsu Onozawa
Tetsuo Akimoto
Yuichiro Ohe
Koichi Goto
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3530-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?

Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer